Pharma roundtable

Assessing R&D, commercial and business development strategies and priorities spanning the cell & gene therapy field

How do we see the 'autologous vs allogeneic vs in vivo' debate playing out? Where does each modality make the most sense commercially and biologically speaking. (Eg. where are the best use cases for autologous, allogeneic and in vivo approaches across solid tumours, autoimmune disease, CD19 and non-CD19 targets, and emerging indications?)